Response of Older Patients with IgE-Mediated Asthma to Omalizumab: A Pooled Analysis

References

• Burrows B, Barbee R A, Cline M G, Knudson R J, Lebowitz M D. Characteristics of asthma among elderly adults in a sample of the general population. Chest 1991; 100: 935–942
   PubMed Web of Science ®Google Scholar
• Enright P L, McClelland R L, Newman A B, Gottlieb D J, Lebowitz M D. Underdiagnosis and undertreatment of asthma in the elderly. Chest 1999; 116: 603–613
   PubMed Web of Science ®Google Scholar
• Mannino D M, Homa D M, Akinbami L J, Moorman J E, Gwynn C. Surveillance for Asthma—United States, 1980–1999. In: Surveillance Summaries, March 29, 2002. MMWR 2002; 51: 1–14, (no. SS-1)
   Google Scholar
• Center for Disease Control. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49: 1–38, (no. RR03)
   Google Scholar
• Dow L, Fowler L, Phelps L, Waters K, Coggon D, Kinmonth A L, et al. Prevalence of untreated asthma in a population sample of 6000 adults in Bristol, UK. Thorax 2001; 56: 472–476
   PubMed Web of Science ®Google Scholar
• Banerjee D K, Lee G S, Malik S K, Daly S. Underdiagnosis of asthma in the elderly. Br J Dis Chest 1987; 81: 23–29
   PubMedGoogle Scholar
• Sin D D, Tu J V. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. Eur Respir J 2001; 17: 380–385
   PubMed Web of Science ®Google Scholar
• Burrows B, Martinez F D, Halonen M, Barbee R A, Cline M G. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320: 271–277
   PubMed Web of Science ®Google Scholar
• Jackola D R, Pierson-Mullany L K, Daniels L R, Corazalla E, Rosenberg A, Blumthal M N. Robustness into advanced age of atopy-specific mechanisms in atopy-prone families. J Gerontol A Biol Sci Med Sci 2003; 58: 99–107
   PubMed Web of Science ®Google Scholar
• Rogers L, Cassino C, Berger K I, Goldring R M, Noman R G, Klugh T, et al. Asthma in the elderly: cockroach sensitization and severity of airway obstruction in elderly nonsmokers. Chest 2002; 122: 1580–1586
   PubMed Web of Science ®Google Scholar
• Crawford W W, Gowda V C, Klaustermeyer W B. Age effects on objective measures of atopy in adult asthma and rhinitis. Allergy Asthma Proc 2004; 25: 175–179
   PubMed Web of Science ®Google Scholar
• Huss K, Naumann P L, Mason P J, Nanda J P, Huss R W, Smith C M, Hamilton R G. Asthma severity, atopic status, allergen exposure, and quality of life in elderly persons. Ann Allergy Asthma Immunol 2001; 86: 524–530
   PubMed Web of Science ®Google Scholar
• Boulet L P, Chapman K R, Cote J, Kalra S, Bhagat R, Swystan V A, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835–1840
   PubMed Web of Science ®Google Scholar
• Fahy J V, Fleming H E, Wong H H, Liu J T, Su J Q, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828–1834
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Wilson S J, Kraft M, Jarjour N N, Steel M, Chang K F, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583–593
   PubMed Web of Science ®Google Scholar
• Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003; 111: 278–284
   PubMed Web of Science ®Google Scholar
• Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20: 1088–1094
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier B Q, McAlary M, Fowler-Taylor A, Cioppa G D, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184–190
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254–61. Erratum in: Eur Respir J 2001; 18: 739–740
   Web of Science ®Google Scholar
• Holgate S T, Chuchalin A G, Hebert J, Lotvall J, Persson G B, Chung K F, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632–638
   PubMed Web of Science ®Google Scholar
• Burrows B, Lebowitz M D, Barbee R A, Cline M G. Findings before diagnoses of asthma among the elderly in a longitudinal study of a general population sample. J Allergy Clin Immunol 1991; 88: 870–877
   PubMed Web of Science ®Google Scholar
• Quadrelli S A, Roncoroni A J. Is Asthma in the elderly really different?. Respiration 1998; 65: 347–353
   PubMed Web of Science ®Google Scholar
• Diette G B, Krishnan J A, Dominici F, Haponik E, Skinner E A, Steinwach S, et al. Asthma in older patients: factors associated with hospitalization. Arch Intern Med 2002; 162: 1123–1132
   PubMed Web of Science ®Google Scholar
• Mannino D, Homa D M, Pertowski C A, Ashizawa A, Nixon L L, Johnson C A, et al. Surveillance for Asthma-United States, 1960–1995. MMWR CDC Surveill Summ 1998; 47: 1–27
   PubMedGoogle Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309–316
   PubMed Web of Science ®Google Scholar
• Vignola A M, Humbert M, Bousquet J, Boulet L P, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59: 709–717
   PubMed Web of Science ®Google Scholar
• National Asthma Education and Prevention Program. United States Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, MD 1997, Expert Panel Report 2. Guidelines for the diagnosis and management of asthma (publication 97-4051)
   Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda 1995, Publication 02-3659 issued January (updated 2002, 2003, 2005)
   Google Scholar
• Freeman P, Liu J, Fox H. Validation of a daily clinical symptom score in asthma, http://www.abstracts2view.com/ats/ Poster presented at: 100th International Conference of the American Thoracic Society; May 24, 2004; Orlando, Florida. [B37] Poster G40. Available at. Accessed November 10, 2006
   Google Scholar
• Kianifard F, Gallo P P. Poisson regression analysis in clinical research. J Biopharm Stat 1995; 5: 115–129
   PubMedGoogle Scholar
• Stokes M E, Davis C S, Koch G G. Categorical Data Analysis Using the SAS System, Second Edition. SAS Institute, Inc, Cary, NC 2000
   Google Scholar
• Law M, Morris J K, Wald N, Luczynska C, Burney P. Changes in atopy over a quarter of a century, based on cross sectional data at three time periods. BMJ 2005; 330: 1187–1188
   PubMed Web of Science ®Google Scholar
• Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S. Pharmacodynamics of omalizumab: implications for optimized dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19: 491–498
   PubMed Web of Science ®Google Scholar
• Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194–1200
   PubMed Web of Science ®Google Scholar
• James A L, Palmer L J, Kicic E, Maxwell P S, Lagan S E, Ryan G F, Musk A W. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005; 171: 109–114
   PubMed Web of Science ®Google Scholar
• Lange P, Scharling H, Ulrik C S, Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 2006; 61: 100–104
   PubMed Web of Science ®Google Scholar
• Moorman J E, Mannino D M. Increasing U asthma mortality rates: who is really dying?. J Asthma 2001; 38: 65–71
   PubMed Web of Science ®Google Scholar